Download as pdf or txt
Download as pdf or txt
You are on page 1of 53

Ranbaxy Global Information Technology SAP at Ranbaxy The Good, The Bad and The Ugly

SAP Summit Mumbai June 6, 2007 David Briskman VP and CIO


Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited

1 1

Agenda
About Ranbaxy IT at Ranbaxy The Good, The Bad and The Ugly
R/3 APO

Q&A

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 2

Ranbaxy Mission Statement

To become a Research based International Pharmaceutical Company

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 3

About Ranbaxy
Over 12,000 Workforce
Princeton NJ, North America

London, Europe

Sales in 125 Countries

Ground Presence in 49 Countries


Singapore Asia Sao Paulo, Brazil South America
Gurgaon ,India

Indias Largest pharmaceutical company Global IT


Privileged and Confidential

2007 Sales ~ US$ 1.6+ bn


Copyright 2008 Ranbaxy Laboratories Limited 4

We Deliver Value Everyday

Business Model
Global Reach
Developed Markets
North America, EU, Japan

Product Portfolio
Generics Branded Generics Branded & OTC

Emerging markets
India, Romania, CIS, Africa

Research & Dev.


New Chemical Entities Generics / NDDS* Complex / Niche/ FTF* The India advantage

Manufacturing
Dosage Form API* - Vertical Integration In-house / Outsource The India advantage

Privileged and Confidential

We Deliver Value Everyday Global IT * NDDS - Novel Drug Delivery System, API Active Pharmaceutical Ingredients, FTF First to File

Copyright 2008 Ranbaxy Laboratories Limited

Global Presence

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 6

Global Manufacturing Presence


25 Plants in 11 Countries
Plants approved by all key regulatory bodies Ability to manufacture complex molecules Quality Engineering Cells operational at all locations High degree of backward integration Stringent quality control and cost leadership Successful partnership with vendors for quality compliance

Romania

USA

China

Ireland Malaysia

Active Pharmaceuticals Ingredients (APIs)Facility, Mohali

Dosage Forms Facility, Paonta Sahib]

India
Nigeria

Global IT
Privileged and Confidential

+South Africa, Japan, Brazil We Deliver Value Everyday

Vietnam
7

Copyright 2008 Ranbaxy Laboratories Limited

Global Supply Chain of Ranbaxy


Suppliers Plants API Formulation Markets

Own Plants (Mohali, Poanta Sahib, Toansa, Dewas) API RM / Advanced Intermediate suppliers

Regional Plants (USA/EUROPE)

In-country stocking points (JAX)

Direct- todistributor API Contract Manufacturers Global Plants (Dewas, Paonta Sahib,Goa, Jejuri)

API suppliers RW (India) Other RM suppliers C&FA (India) Stockists

PM Suppliers

Contract Manufacturer / Third Party / FG Imported

Global IT
Privileged and Confidential

We Deliver Value Everyday

API customers
8

Copyright 2008 Ranbaxy Laboratories Limited

Supply Chain Complexity


Suppliers Plants API Formulation Markets

Supply Side Own Plants (Mohali, Complexity Poanta Sahib,


Toansa, Dewas) API RM / Advanced Intermediate suppliers

Regional Plants (USA/EUROPE)

In-country stocking points (JAX)

API suppliers

Other RM suppliers

Backward Integrated (21 DF & API plants) 40+ API Contract Contract Manufacturers Manufacturers 30+ Third Party Suppliers ~ 1000+ Raw Materials 15000+ Packaging Materials

Demand Side Complexity


Direct- todistributor

Global Plants (Dewas, Paonta Sahib,Goa, Jejuri)

Customers in 125 countries 6 Distribution models ~7000 SKUs 3 new product introductions RW C&FA (India) per day
(India)

Stockists

PM Suppliers

Contract Manufacturer / Third Party / FG Imported

Global IT
Privileged and Confidential

We Deliver Value Everyday

API customers
9

Copyright 2008 Ranbaxy Laboratories Limited

Research & Development


Dedicated Facilities for Innovative & Generics Research > 1400 R&D Personnel ( ~ 250 PhDs) 8-10 NCE molecules in pipeline 4 NDDS platform technologies ~ $ 100 Mn total spend (6.4% to sales)

Collaboration in Drug Discovery Research (DDR) R&D I Out-licensing in DDR R&D II

Out-licensing in Novel Drug Delivery Systems

Global IT
Privileged and Confidential

We Deliver Value

R&D EverydayIII

R&D IV
10

Copyright 2008 Ranbaxy Laboratories Limited

Global Sales (2005 - 2008e)


CAGR* ~ 19%
$ Mn

2000
1607

~ 1900 e

1600
1339 1178

1200

800

400

Global IT
Privileged and Confidential

2005

2006 2007 We Deliver Value Everyday

2008
e - estimate 11

Copyright 2008 Ranbaxy Laboratories Limited * 3 year CAGR on like-to-like basis .i.e. excluding allied businesses divested in 2005

Recent Acquisitions & Alliances

Terapia (Romania) Be-Tabs (South Africa) Allen (Italy) Ethimed (Belgium) Mundogen (Spain)
Derma Brands (BMS)

Zenotech (India) Krebs (India) Jupiter Biosciences(Ind.) Cardinal Drugs (India) Orchid Pharma (India) Auto-injector Tech.(USA)

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 12

IT Top Priorities
People Retention, Development and Recruitment Accelerate Product to Market Time Enable Supply Chain Excellence Deliver Business Intelligence

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 13

IT Overview at Ranbaxy
Mix of enterprise applications like SAP R/3, APO, BW, Pharma-co-vigilance, Document Management, Sales Force Automation and host of local applications including

workflows based applications and a strong web presence A highly scalable and fault-tolerant Infrastructure across the globe MS Exchange as global communication platform Major thrust on Information Security Business Continuity Plans for key systems Disaster Recovery setup for SAP R/3 environment.
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 14

Global Infrastructure Foot print

Swede n UK Canada Ireland Germany France Poland Ukraine Belgium Portugal Spain US Mexico Senegal Guatemala Ivory Coast Nigeria Cameroon Morocco

Russi Lithuani a Latvia a Belarus Austria Romania Italy Hungar y Egypt UAE Sri Ugand Lanka a Kenya Malaysia Mauritiu s Zimbabw e South Africa Kazakhsta n China Nepal Myanm India ar Vietnam Thailand

Japan

Bulgaria

Cambodi a Singapor e

Peru

Brazil Namibia

Ranbaxy Locations - 49 Overseas Locations with Exchange Server - 10 Locations With RPC \ Http from Corporate - 12 SAP R3 Locations - 19

Australia

Global IT

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 15

Privileged and Confidential

11-Jun-08

2007 Operating Statistics Keeping the Lights On


IT Helpdesk Handles Approx 110, 000 calls annually and resolve 99% within SLA period Typical month has 15 million external attacks and 3500 Virus Attacks IT Firewall Protects the business

2000 SAP users doing > 3,000,000 transactions in SAP annually

Global Data Centers having > 425 Servers across enterprise with averaged uptime 99.5% Keeping the Business Connected

10000 Userids & Mailboxes managed globally

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 16

Some Certifications
Focus on IT Security & Processes First major Pharma organization in India to get certification

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 17

Some Certifications

SAP CCC
Focus on SAP Support Processes and Documentation First company in Asia pacific to get certified by SOCA route First company in India to get recertified 3rd time
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 18

SAP R/3 is our Transactional Backbone

Privileged and Confidential

~ 75% of global turnover and more than 100 sites worldwide run SAP We Deliver Value Everyday Global IT One System - Global Single Instance
Copyright 2008 Ranbaxy Laboratories Limited

19

RANBAXY: SAP Overview


SAP R/3 Footprint All the modules of SAP R/3 are implemented and used. Single R/3 instance used globally. 17 Company Codes and 12 Representative Offices 12 Manufacturing Plants; Various C&F and Warehousing Locations and Logistics Partners SAP R/3 System Metrics 2.3 TB in a single central R/3 database. Live in > 100 locations across globe with 1900+ users. 8,50,000+ dialog steps / day 0.8 seconds average dialog response time. 99.9% Uptime.
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 20

Current Ranbaxy Locations using SAP R/3


Company Codes (21) India (1), USA(6), UK(1), Ireland(1), Fr ance(2), Germany(1), Russia(1), Malaysia(1), Canada (1), Belgium (1) Sweden (1) China (1), South Africa (3) Representative Offices (12) Asia(3), Africa(3), CIS(6) Manufacturing Plants (14) India(8), US(2), Ireland(1), Malay sia(1) China (1), South Africa (1) C&F Locations (44) India (C&F 39, RWH 3, IDWH 2) Global IT
Privileged and Confidential

Logistics Partners Germany (caremaxx), UK (CPD Logistics) France (CSP - batch process)

Subcontractors & Loan Licensees India(4) 59 LLs and 25 Subcontractors through Back Office

Shared Service for Accounts Payable

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 21

SAP Components Used / Under Implementation


R/3 4.6c MS Windows 2003 MS SQL 2000 ~ 1900 Users ~ 100 Locations ~ All Modules
Global IT
Privileged and Confidential

SCM 4.0 HP-UX / Oracle ~ SNP ~ PPDS ~ DP

BW 7.0 CRM 4.0 XI 3.0 EP 7.0 SEM 6.0 HR 4.6c Solution Manager 4.0

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 22

SAP R/3 Journey in Ranbaxy


Russia, Romania, Poland, Brazil - 2009 ECC Upgrade & Rollouts - 2008, South Africa 2008 Belgium, Sweden, China- 2007 Malaysia 2006 Germany, Rep Offices 2005 France, Russia (Front Office) 2004 Ireland, UK, LLs / CMs in India 2003 4.6.c Upgrade 2002 Complete India 2001 US 2000 First go-live in India April 1999 Project Start April 1998
We Deliver Value Everyday
Copyright 2008 Ranbaxy Laboratories Limited 23

DONE TOTAL AROUND 100 SITES

Global IT
Privileged and Confidential

SAP R/3 System Statistics


Number of HR Records Number of User Exits Number of Z-Programs Number of Transactions steps per day Number of Unique transactions per day Number of Sales related Orders Per day Number Purchase related Orders per day Number of Goods Receipts per day Number of Material Movements per day Number of Process Orders per day Number of Plant Maintenance orders per day Number of Inspection Lots per day 20900 103 3071 920000- 930000 2200- 2300 3200 355 1350 6630 580 200 250 872

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 24

SAP Resourcing
One global team (CoE) under single head with people in India, US and EU (primarily India) Day-to-Day Support is offshored in India All Implementations done with internal team APO Internal Team with partner for support New Age Products Internal Team with spot expertise External expertise is used to augment internal team only when required
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 25

SAP R/3 at Ranbaxy

It is good to know which is which

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 26

R/3 The Good


CCC 3 consecutive times and SAP ACE 2007 System enablement of Shared Services: 2006-07 Electronic Banking and EDI (charge backs etc) Streamlining and uniformity of processes across organization Faster integration with new entities / M&A Online analysis of Supply Chain performance based on several Key Performance Indicators Online reporting of inventory, sales and receivables resulting into enhanced productivity Successful handling of Multi Lingual SAP settings Successful management of Statutory and regulatory checks and audits by having systematic processes in place
We Deliver Value Everyday
Copyright 2008 Ranbaxy Laboratories Limited 27

Global IT

Privileged and Confidential

R/3 The Good


Digitization of approval process - use of workflows Centralized database for masters and transactional data resulting into Enhanced visibility and control on Global Spend Electronic Banking is used in most of the locations using automatic payments System based Audits Enables selling in regulated markets

Overall SAP has led to increase in sales, reduction in inventory, increase in productivity etc.
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 28

SAP Returns Macro Level


Quantified Savings in Many Areas: 1. Increase in Sales In US due to integration with customers In India due to integration with CFAs 2. 3. 4. Reduction in receivables Reduction in inventory Savings due to productivity

ROI estimated at 200%


Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 29

R/3 The Bad


R/3 is still cumbersome to use Perception of value still requires effort Data rich but information poor For small sites it is digging a small hole with a back hoe

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 30

R/3 The Ugly


Master Data Material Codes Vendor Codes Customer Numbers Total Number of Recipes User Roles 235,700 77860 116960 59871 9000

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 31

SAP R/3 at Ranbaxy Next Steps


Complete ECC 6.0 Upgrade Complete BW & SEM Implementations
Financial Consolidation Common and Market Specific KPI Dashboards Business Planning and Simulation

Complete R/3 Roll-outs to top markets Clean-up Master Data Application consolidation of minor systems Plan HR ESS Deployment

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 32

Commencement of APO
Key driver for implementing an APO at Ranbaxy was the increasing complexity of the Supply Chain due to rapid business growth.
FG SKUs: >7000 Active RM+PM SKUs: >20000 Active Countries: >100 Manufacturing plants: 16 own DF plants, 5 own API plants and > 40 Contract Manufacturers and Loan Licensees 4 New Products introduced everyday

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 33

Project Objectives and Expectations


Supply chain Planning for Enhancing Customer service To Ranbaxys Universal Markets

Immediate Objectives
Transform the supply chain to substantially improve customer service levels in the short term whilst maintaining optimal inventory levels
APO Implementation Provide integrated planning capability Improve analytical capabilities such as What-If analysis Provide automation of planning tasks Sustain/enhance Spectrum benefits

Spectrum

Provide End to end Supply Chain Visibility Increase flexibility and responsiveness of supply chain Support Ranbaxys vision and growth plan

Medium Term Objectives


Build Ranbaxys supply chain capability to be a source of competitive advantage the global generics market

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 34

SPECTRUM+ : Implementation of APO


Project Spectrum+ started in April 2004 to implement SAP APO at 5 markets and six manufacturing plants to cover:
Forecasting Distribution Requirement Planning Deployment Planning Production Planning and Detailed Scheduling

APO Modules to be implemented:


DP (Demand Planning) SNP (Supply Network Planning) PPDS (Production Planning and Detailed Scheduling)

Overall project duration


Spectrum Spectrum+ Global IT
Privileged and Confidential

: 12 months (starting April 2003) : 30 months (starting April 2004)


We Deliver Value Everyday
Copyright 2008 Ranbaxy Laboratories Limited 35

Overview of APO Architecture at Ranbaxy


APO (Advanced Planner and Optimizer) is an integrated suite of modules covering all key functional areas within Supply Chain Planning area.

SAP-SCM(APO)
Demand Planning Supply Network Planning Production Planning/ Detailed Sch. Scheduling Available To Promise Transportation Planning

BW

Integration Layer

Transaction System

Non R\3 Transaction System


36

Source: SAP

Global IT

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited

Privileged and Confidential

Current APO Planning Statistics


Demand Planning Product Locations Planned: >90000 Locations Planned: >150 SKUs Planned: >10000 Number of Jobs run >500 pm Supply Planning FG SKUs Planned: > 7000 RM SKUs Planned: > 20000 Work Centers Planned: >1500

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 37

APO at Ranbaxy - The Good


First Market rollout took place in March 2005. Rollouts happened at the following markets and plants till December 2006: Markets: India, US, UK Germany, Russia & CIS Plants: DF Dewas; API Mohali, Dewas, Toansa Measurable results being realized in Forecast Accuracy and Improved Customer Service Project continues to deliver results as it is deployed to more markets
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 38

APO at Ranbaxy - The Bad


Project has taken much longer than expected Significant issues with maintaining both internal and external expertise base Early customizations causing on-going support requirements After 2 years, project team lost focus

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 39

APO at Ranbaxy The Ugly


Original Implementation Partner Fall-Out Project got Lost for 12 months PPDS was over-engineered to solve everything and did not deliver workable schedules Steering Teams focused on technical issues Project was perceived as failure

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 40

For a Few Dollars More..


Called in SAP Value Engineering

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 41

What did Value Engineering Find


Supply Chain
RM & PKG Suppliers Matls Invent. Purchase Orders Inventory Turns API Mfg. DF Mfg. BSR Logistics BSR Invent. GIT Regl W/H CFAs Regl Invent. Regl Office/ Customers

DF Schedule NDR - API Mfg. Commits Commit Vs. Actual SC/MFG NDR Global NDR-Plant Requirement Vs. Commit SC

Process

Demand Forecast

KPIs & Org. RM/PKG Purch.


WIP - MFG

FG Inventory Turns SC

Fcast Accuracy Marketing

DIFOT Markets

DF API - SC API FG MKTG/MFG

Benefits from Spectrum


1. Standard process across the enterprise for improved accountability/ownership, structured/timely planning, and coordination/communication across the supply chain 2. Cross functional SC organization for process management, monitoring and KPI reporting 3. S&OP Process to resolve as many discrepancies and mismatches as possible early in planning 4. Initial improvements and business benefits, but system wide benefits not fully realized

Opportunities for Improvement in Spectrum+


1. Improve visibility and velocity of information on a single platform for a flexible and responsive SCM system. 2. Increase type and detail of data needed for exception mgmt (e.g. opport.. demand) and prioritization (e.g. MTO) 3. Early S&OP process to minimize surprises and achieve more efficient supply-demand mismatch 4. Longer/detailed planning horizon to improve optimization opportunities (e.g. Mode mix, mode selection, procurement)

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 42

VE Recommendations for Spectrum+: Summary


Area SAP APO PPDS Project Objectives & Ownership Issues & Concerns Functionality gaps and product usage issues Implementation objectives Sr. Executive ownership Recommendation SAP to assess architecture and recommend resolution to key PPDS issues Revise objectives from Spectrum Automation to Single SC Platform Across Ranbaxy Senior Ranbaxy Executive to own and drive Spectrum+ implementation and roll out SAP Executive support in issue resolution Committed project team of SMEs and product experts for PPDS and SCM Ensure stakeholder ownership and participation during development, roll-out and adoption Address training requirements and put in place an on-going APO support organization Focus on integrating the solution components and then increasing depth Focus on key markets and DF manufacturing Improved order promising and fulfillment Manage supplier base and DM purchasing

SAP Support SAP Executive support Subj. Matter Expertise Change Ranbaxy end user & usage of Management system Adoption across enterprise and continuous improvement Implementati Focus within business functions on Scope & Vertical Integration Focus Future Capabilities Order Promising Supplier Relationship Management

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 43

Spectrum+ and APO


At key decision point
Re-invest or Divest

Critical Issues
Ranbaxy Senior Executive Ownership SAP Support and APO Capability Change Management and Project Team Burnout

Value Engineering Study Conducted


Significant Value Exists Recommended SAP Proof of Concept with Waldorf Supply Chain Center of Excellence

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 44

The Cavalry Arrived.


Engaged the SAP Supply Chain CoE Evaluated requirements, model, configuration and results In 10 weeks, delivered re-engineered model and configuration changes Implemented in 2 planning cycles

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 45

Dewas Performance Post APO PPDS Re-launch in May 07


Improved C Vs A: Dewas has consistently delivered C (Commits) Vs A (Actual) of above 90% since May 2007

May: 94% July: 90%

June: 90% August: Expected to be >=90%

Increase in Throughput: Number of SKUs delivered by Block B used to average between 250-275. Since May, this has gone up to 280-300 with a maximum of 306 in May 2007. Reduction in PM Inventory: There has been a reduction in PM inventory in Dewas to the tune of Rs. 2.4 Cr over May-July 2007. This can primarily be attributed to APO based planning. Dewas is still in stabilization stage. Results shall improve further. Global IT
We Deliver Value Everyday
Copyright 2008 Ranbaxy Laboratories Limited 46

Privileged and Confidential

Addressing the Key Issues


PPDS Functionality / Capability
Proof of Concept with SAP CoE delivered results

Sponsorship
COO engaged actively to spearhead project

Change Management
Project Management changed Once there were demonstrable results, people wanted to be associated with success Moved key project team members into operations

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 47

APO Key Learnings


Do Not Get Off-Track Do Not Boil the Ocean When in doubt Get SAP Involved Value Engineering should be engaged Recognize the White Elephant in the room As with all SCM Projects There is no black box magic solution, have realistic expectations Fix R/3 First Where Possible - GIGO You do not need R/3 implemented everywhere to roll-out APO and deliver results
Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 48

Next Steps with APO


DP/SNP deployment completion to Rest of World by End 08 PPDS Deployment to existing Dosage Form facilities 1 done, 1 in process Upgrade to SCM 7.0 and reduce original customizations in 2008 Reduce planning cycle time and frequency Continue to quantify business results

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited 49

As in the movie.

Work with the Ugly Overcome the Bad Keep focused on the gold And you will be the Good
We Deliver Value Everyday
Copyright 2008 Ranbaxy Laboratories Limited 50

Global IT
Privileged and Confidential

Ranbaxy Global Information Technology

We Deliver Value Everyday!


Questions ?

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited

51 51

Ranbaxy Global Information Technology

We Deliver Value Everyday!


Thank You! Interested in Joining our Winning Team E-mail: david.briskman@ranbaxy.com

Global IT
Privileged and Confidential

We Deliver Value Everyday


Copyright 2008 Ranbaxy Laboratories Limited

52 52

Copyright 2008 SAP AG All rights reserved


No part of this publication may be reproduced or transmitted in any form or for any purpose without the express permission of SAP AG. The information contained herein may be changed without prior notice. Some software products marketed by SAP AG and its distributors contain proprietary software components of other software vendors. SAP, R/3, xApps, xApp, SAP NetWeaver, Duet, SAP Business ByDesign, ByDesign, PartnerEdge and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries all over the world. All other product and service names mentioned and associated logos displayed are the trademarks of their respective companies. Data contained in this document serves informational purposes only. National product specifications may vary. The information in this document is proprietary to SAP. This document is a preliminary version and not subject to your license agreement or any other agreement with SAP. This document contains only intended strategies, developments, and functionalities of the SAP product and is not intended to be binding upon SAP to any particular course of business, product strategy, and/or development. SAP assumes no responsibility for errors or omissions in this document. SAP does not warrant the accuracy or completeness of the information, text, graphics, links, or other items contained within this material. This document is provided without a warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. SAP shall have no liability for damages of any kind including without limitation direct, special, indirect, or consequential damages that may result from the use of these materials. This limitation shall not apply in cases of intent or gross negligence. The statutory liability for personal injury and defective products is not affected. SAP has no control over the information that you may access through the use of hot links contained in these materials and does not endorse your use of third-party Web pages nor provide any warranty whatsoever relating to third-party Web pages

Weitergabe und Vervielfltigung dieser Publikation oder von Teilen daraus sind, zu welchem Zweck und in welcher Form auch immer, ohne die ausdrckliche schriftliche Genehmigung durch SAP AG nicht gestattet. In dieser Publikation enthaltene Informationen knnen ohne vorherige Ankndigung gendert werden. Einige von der SAP AG und deren Vertriebspartnern vertriebene Softwareprodukte knnen Softwarekomponenten umfassen, die Eigentum anderer Softwarehersteller sind. SAP, R/3, xApps, xApp, SAP NetWeaver, Duet, SAP Business ByDesign, ByDesign, PartnerEdge und andere in diesem Dokument erwhnte SAP-Produkte und Services sowie die dazugehrigen Logos sind Marken oder eingetragene Marken der SAP AG in Deutschland und in mehreren anderen Lndern weltweit. Alle anderen in diesem Dokument erwhnten Namen von Produkten und Services sowie die damit verbundenen Firmenlogos sind Marken der jeweiligen Unternehmen. Die Angaben im Text sind unverbindlich und dienen lediglich zu Informationszwecken. Produkte knnen lnderspezifische Unterschiede aufweisen. Die in diesem Dokument enthaltenen Informationen sind Eigentum von SAP. Dieses Dokument ist eine Vorabversion und unterliegt nicht Ihrer Lizenzvereinbarung oder einer anderen Vereinbarung mit SAP. Dieses Dokument enthlt nur vorgesehene Strategien, Entwicklungen und Funktionen des SAP-Produkts und ist fr SAP nicht bindend, einen bestimmten Geschftsweg, eine Produktstrategie bzw. -entwicklung einzuschlagen. SAP bernimmt keine Verantwortung fr Fehler oder Auslassungen in diesen Materialien. SAP garantiert nicht die Richtigkeit oder Vollstndigkeit der Informationen, Texte, Grafiken, Links oder anderer in diesen Materialien enthaltenen Elemente. Diese Publikation wird ohne jegliche Gewhr, weder ausdrcklich noch stillschweigend, bereitgestellt. Dies gilt u. a., aber nicht ausschlielich, hinsichtlich der Gewhrleistung der Marktgngigkeit und der Eignung fr einen bestimmten Zweck sowie fr die Gewhrleistung der Nichtverletzung geltenden Rechts. SAP bernimmt keine Haftung fr Schden jeglicher Art, einschlielich und ohne Einschrnkung fr direkte, spezielle, indirekte oder Folgeschden im Zusammenhang mit der Verwendung dieser Unterlagen. Diese Einschrnkung gilt nicht bei Vorsatz oder grober Fahrlssigkeit.

Global IT

Die gesetzliche Haftung bei Personenschden oder die Produkthaftung bleibt unberhrt. Die Informationen, auf die Sie mglicherweise ber die in diesem Material enthaltenen Hotlinks zugreifen, unterliegen nicht dem Einfluss von SAP, und SAP untersttzt nicht die Nutzung von Internetseiten Dritter durch Sie und gibt keinerlei Gewhrleistungen oder Zusagen ber Internetseiten Dritter ab.

We Deliver Value Everyday

Alle Rechte vorbehalten. Privileged and Confidential SAP Summit

Copyright 2008 Ranbaxy Laboratories Limited

53

You might also like